Furuya H, Ishibashi R, Wakayama T, Ohguni S, Notsu K, Takagi C, Kato Y
Department of Medicine, Shimane Medical University.
Rinsho Ketsueki. 1992 Sep;33(9):1172-7.
Subcutaneous administration of recombinant human Interleukin-1 beta (IL-1 beta) in a dose of 1-3 x 10(4) U/day for 14 to 72 days resulted in an increase in circulating granulocytes and bone marrow monocytes in all the 4 patients examined. Circulating platelet count was also increased in two of four patients with myelodysplastic syndrome (MDS) and aplastic anemia (AA). Bone marrow examination revealed an increase in megakaryocyte count in these patients, whereas the percentage of blast was not changed. An increase in blood platelet count was accompanied by an increase in serum GM-CSF in a patient with AA, whereas serum IL-6 level was not changed throughout the treatment with IL-1 beta. These findings suggest that IL-1 beta may be useful for the treatment of a proportion of patients with MDS and AA who are associated with thrombocytopenia.
以1 - 3×10⁴单位/天的剂量皮下注射重组人白细胞介素 - 1β（IL - 1β），持续14至72天，结果显示，在所检查的4例患者中，循环粒细胞和骨髓单核细胞均增加。4例骨髓增生异常综合征（MDS）和再生障碍性贫血（AA）患者中有2例的循环血小板计数也增加。骨髓检查显示这些患者的巨核细胞计数增加，而原始细胞百分比未改变。AA患者血小板计数增加的同时，血清粒细胞 - 巨噬细胞集落刺激因子（GM - CSF）增加，而在整个IL - 1β治疗过程中，血清白细胞介素 - 6（IL - 6）水平未改变。这些发现表明，IL - 1β可能对部分伴有血小板减少症的MDS和AA患者的治疗有用。
